Treatment nationalism is a threat to us all.
L’expertise universitaire, l’exigence journalistique
Articles sur Vaccines
Affichage de 541 à 560 de 789 articles
Vaccines and antivirals aren’t the only game in town.
A mutating coronavirus has implications for vaccines, treatments, tests and your future plans.
The smallpox vaccination used calf lymph, which was unacceptable to vegetarians and anti-vivisectionists who were growing in number from the mid 19th century.
A century ago, the influenza pandemic killed about 50 million people. Today we are battling the coronavirus pandemic. Are we any better off? Two social scientists share five reasons we have to be optimistic.
Should the US be able to pre-order vaccines for its citizens when other populations around the globe are at greater risk?
To find a SARS-CoV-2 vaccine, scientists need to work hands-on with the highly infectious coronavirus. It happens in a super secure lab designed to keep them safe and prevent any escapes.
Without a vaccine, the cost of reaching herd immunity during a pandemic is counted in lives lost, and it won’t quickly stop the virus’s spread.
If your immunisation record is incomplete, you might repeat a vaccination unnecessarily, or miss out on government support, child care, or work. So it pays to check.
Just focusing on spike proteins might not offer the complete immunity.
What happens when we have a COVID-19 vaccine – and millions are afraid of a needle?
There is a growing call for so-called challenge trials to speed up vaccine development.
Researchers are developing a seasonal shot that blocks Lyme disease-causing bacteria from a tick.
Early clinical trials into ginseng, rhubarb and rice paved the way for testing coronavirus treatments today.
Tobacco has imposed a terrible toll on global health, but it could be used to produce the molecules we need to fight COVID-19.
A unique challenge is emerging in the search for a COVID-19 vaccine: how to balance intellectual property rights with serving the public good.
Amazon and General Motors are among companies exploring ways to test employees for COVID-19 infection, but these measures may be against the law.
A potential vaccine for coronavirus is undergoing a human trial in Australia. It’s based on a vaccine that was already in development for influenza, and has shown promise in animal studies.
Long after a crisis recedes, residual anxiety can remain and become calcified in cultures, customs and institutions.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Les contributeurs les plus fréquents
-
Professorial Fellow, University of Canberra
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Associate Professor of Biology, Rochester Institute of Technology
-
Professor of Microbiology, School of Medicine, University of Washington
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Lecturer in Virology, Queen's University Belfast
-
Professor, Discipline of Paediatrics and Child Health, University of Sydney
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Assistant Professor of Political Science, Oklahoma State University
-
Professor of Immunology, RMIT University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Senior Lecturer; MD, Victoria University
